Marketing-authorisation holder · United States
Bioverativ Therapeutics, Inc.
23 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
23 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Alprolix250iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2016 |
| Alprolix3000iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2014 |
| Alprolix4000iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2016 |
| Alprolix1000iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2014 |
| Alprolix2000iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2014 |
| Alprolix500iu · For Injection | Coagulation factor ix fc fusion protein | United States | Marketed | 2014 |
| ALTUVIIIO750iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO500iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO250iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO3000iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO2000iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO4000iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| ALTUVIIIO1000iu · For Injection | Antihemophilic factor fc-vwf-xten fusion protein | United States | Marketed | 2023 |
| Eloctate1000iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate6000iu · For Injection | Antihemophilic factor | United States | Marketed | 2017 |
| Eloctate4000iu · For Injection | Antihemophilic factor | United States | Marketed | 2017 |
| Eloctate1500iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate500iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate3000iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate2000iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate250iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate750iu · For Injection | Antihemophilic factor | United States | Marketed | 2014 |
| Eloctate5000iu · For Injection | Antihemophilic factor | United States | Marketed | 2017 |